Are severe adverse events commonly observed in dogs during cancer chemotherapy? A retrospective study on 155 dogs.
canine
chemotherapy
oncology
side effects
toxicity
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
28
10
2021
received:
30
09
2021
accepted:
30
10
2021
pubmed:
15
11
2021
medline:
18
5
2022
entrez:
14
11
2021
Statut:
ppublish
Résumé
Overall prevalence of severe adverse events (sAE) has been poorly studied in veterinary medicine and peer-reviewed studies mostly focused on a single protocol, making it difficult to have a general overview. The aim of this retrospective study was to assess the frequency and risk factors of sAE secondary to various protocols of chemotherapy in dogs. Medical records of 155 dogs receiving chemotherapy between January 2013 and December 2018 were reviewed. Adverse events (AE) were graded according to Veterinary Comparative Oncology Group-common terminology criteria for AE (VCOG-CTCAE) grading system. Statistical analyses were performed to determine whether demographic, cancer type and chemotherapy protocol were associated with development of sAE and their consequences. AE were reported at least once in 124 (80%) dogs and sAE were observed in 50 (32.3%) dogs. Among them, 23 (14.8%) had gastro-intestinal and 31 (20.0%) had myelotoxic events. sAE led to hospitalisation in 37 (23.9%) dogs, to chemotherapy arrest in 12 (7.7%) dogs and to euthanasia or death in 9 (5.8%) dogs. Haematopoietic tumours were statistically associated with a higher frequency of sAE (p = .004), gastrointestinal sAE (p = .009) and hospitalisation (p = .004). A body weight over 10 kg was associated with less haematological sAE (p < .001). The use of a multi-agent protocol was highlighted as a risk factor for sAE (p = .038) and haematological sAE (p < .001). sAE following chemotherapy and leading to hospitalisation, chemo arrest or death were relatively common. A special attention during chemotherapy follow-up should be given to small dogs and those receiving multi-agent protocol or treated for haematopoietic tumours.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-403Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Chabner BA. Clinical strategies for cancer treatment: the role of drugs. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice. 5th ed. Lippincott Williams & Wilkins; 2011:3-14.
Gustafson DL, Bailey DB. Cancer chemotherapy. In: Withrow SJ, Vail DM, Page RL, eds. Withrow & MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier; 2013:182-208.
Tew KD, Reed E, Saif MW, et al. Pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 8th ed. Lippincott Williams & Wilkins; 2008:407-456.
LeBlanc AK, Atherton M, Bentley RT, et al. Veterinary cooperative oncology group-common terminology criteria for adverse events (VCOG-CTCAE v1.0) following chemotherapy or biological antineoplastic therapy in dogs and cats. Vet Comp Oncol. 2004;2(4):195-213.
Chun R, Garrett LD, Vail DM. Cancer chemotherapy. In: Withrow SJ, MacEwen EG, eds. Withrow & MacEwen's Small Animal Clinical Oncology. 4rd ed. Elsevier; 2007:163-192.
Cunha SCS, Silva FBF, Corgozinho KB, et al. Adverse effects of chemotherapy in dogs. World Vet J. 2017;7(3):74-82.
Sorenmo KU, Baez JL, Clifford CA, et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. J Vet Intern Med. 2004;18(2):209-213.
Ahaus EA, Couto CG, Valerius KD. Hematological toxicity of doxorubicin-containing protocols in dogs with spontaneously occurring malignant tumors. J Am Anim Hosp Assoc. 2000;36(5):422-426.
Arrington KA, Legendre AM, Tabeling GS, et al. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin in dogs. Am J Vet Res. 1994;55(11):1587-1592.
Ogilvie GK, Richardson RC, Curtis CR, et al. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc. 1998;195(11):1584-1587.
Wouda RM, Borrego J, Keuler NS, Stein T. Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs. Vet Comp Oncol. 2016;14(1):67-80.
Gillem J, Giuffrida M, Krick E. Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013). Vet Comp Oncol. 2017;15(2):400-410.
Lane AE, Black MI, Wyatt KM. Toxicity and efficacy of a novel doxorubicin and carboplatin protocol for the treatment of canine appendicular osteosarcoma following limb amputation. Aust Vet J. 2012;90(3):69-74.
Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med. 1997;11(5):279-283.
Ogilvie GK, Moore AS, Chen C, et al. Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study. J Am Vet Med Assoc. 1994;205(4):570-573.
Ogilvie GK, Straw RC, Powers BE, Cooper MF, Withrow SJ. Prevalence of nephrotoxicosis associated with a short-term solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987-1989). J Am Vet Med Assoc. 1991;199(5):613-616.
Stiborova K, Treggiari E, Amores-Fuster I, et al. Haematologic toxicity in dogs with mast cell tumours treated with vinblastine/prednisolone chemotherapy with or without radiotherapy. J Small Anim Pract. 2019;60(9):534-542.
Robat C, London C, Bunting L, et al. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia ®) in dogs: a phase I dose-finding study. Vet Comp Oncol. 2012;10(3):174-183.
Rassnick KM, Bailey DB, Russel DS, et al. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade metastatic, nonresectable mast cell tumours. Vet Comp Oncol. 2010;8(2):138-152.
Bailey DB, Rassnick KM, Kristal O, Chretin JD, Balkman CE. Phase I dose escalation of single-agent vinblastine in dogs. J Vet Intern Med. 2008;22(6):1397-1402.
Grant IA, Rodriguez CO, Kent MS, et al. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. J Vet Intern Med. 2008;22(2):388-393.
Poirier VJ, Burgess KE, Adams WM, Vail DM. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004;18(4):536-539.
Bavcar S, De Vos J, Kessler M, et al. Combination toceranib and lomustine shows frequent high-grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: a European multicentre study. Vet J. 2017;224:1-6.
Heading KL, Brockley LK, Bennett PF. CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07). Aust Vet J. 2011;89(4):109-116.
Kristal O, Rassnick MK, Gliatto JM, et al. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern Med. 2004;18(1):75-80.
Parsons-Doherty M, Poirier VJ, Monteith G. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma. Can Vet J. 2014;55(2):175-180.
Guillen A, Finotello R, Wynne P, et al. Toxicity of cytarabine constant rate infusion in dogs with high-grade non-Hodgkin lymphoma with bone marrow or central nervous system involvement. Aust Vet J. 2020;98(3):69-78.
Wang S, Lee J, Liao AT. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma. Can Vet J. 2016;57(3):271-276.
Soremno K, Overley B, Krick E, et al. Outcome and toxicity associated with dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Vet Comp Oncol. 2010;8(3):196-208.
Greenberg B, Boria PA, Borgatti-Jeffreys A, Raskin RE, Lucroy MD. Phase II clinical trial of combination chemotherapy with dexamethasone for lymphoma in dogs. J Am Anim Hosp Assoc. 2007;43(1):27-32.
MacDonald VS, Thamm DH, Kurzman ID, Turek MM, Vail DM. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med. 2005;19(5):732-736.
Tomiyasu H, Takahashi M, Fujino Y, et al. Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol. J Vet Med Sci. 2010;72(11):1391-1397.
Ji N, Song J, Hwang T, et al. A study of gastrointestinal and bone marrow adverse events after administration of various chemotherapeutic agents in canine malignant tumor patients. J Vet Clin. 2019;36(1):30-37.
Price GS, Frazier DL. Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: I. Potential problems with current BSA formulae. J Vet Intern Med. 1998;12(4):267-271.
Frazier DL, Price GS. Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: II. Limitations imposed by pharmacokinetic factors. J Vet Intern Med. 1998;12(4):272-278.
Page RL, Macy DW, Thrall DE, et al. Unexpected toxicity associated with the use of body surface area for dosing melphalan in the dog. Cancer Res. 1988;48:288-290.
Sorenmo KU, Harwood LP, King LG, et al. Case-control study to evaluate risk factors for the development of sepsis (neutropenia and fever) in dogs receiving chemotherapy. J Am Vet Med Assoc. 2010;236(6):650-656.
Richardson D, Poirier VJ, Matsuyama A, et al. Correlation between body weight and mitoxantrone-associated neutropenia in dogs. J Am Anim Hosp Assoc. 2018;54(3):144-149.
Coffee C, Roush JK, Higginbotham ML. Carboplatin-induced myelosuppression as related to body weight in dogs. Vet Comp Oncol. 2020;18(4):804-810.
Nebeker JR, Barach P, Samore SH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795-801.
Ingrand I, Defossez G, Lafay-Chebassier C, et al. Serious adverse effects occuring after chemotherapy: a general cancer registry-based incidence survey. Br J Clin Pharmacol. 2020;86(4):711-722.
Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci. 2006;68(6):581-587.
Boria PA, Murry DJ, Bennett PF, et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc. 2004;224(3):388-394.
Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol. 2005;3(2):73-80.
Hosoya K, Kisseberth WC, Alvarez FJ, et al. Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors. J Am Anim Hosp Assoc. 2009;45(1):14-18.
Burkholder WJ, Toll PW. Obesity. In: Hans MS, Thatcher CD, Remillard RL, Roudebush P, eds. Small Animal Clinical Nutrition. Mark Morris Institute; 2000:401-430.
Mason SL, Grant IA, Elliott J, et al. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomized controlled study. J Small Anim Pract. 2014;55(8):391-398.
Fournier Q, Serra JC, Williams C, et al. Chemotherapy-induced diarrhoea in dogs and its management with smectite: results of a monocentric open-label randomized clinical trial. Vet Comp Oncol. 2021;19(1):25-33.
Marrington AM, Killick DR, Grant IA, et al. Toxicity associated with epirubicin treatment in a large case series of dogs. Vet Comp Oncol. 2012;10(2):113-123.
Rau SE, Barber LG, Burgess KE. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. J Vet Intern Med. 2010;24(6):1452-1457.
Frimberger AE, Chan CM, Moore AS. Canine osteosarcoma treated by post-amputation sequential accelerated doxorubicin and carboplatin chemotherapy: 38 cases. J Am Anim Hosp Assoc. 2016;52(3):149-156.
Bailey D, Erb H, Williams D, Ruslander D, Hauck M. Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. J Vet Intern Med. 2003;17(2):199-205.
Olsen JA, Thomson M, O'Connell K, Wyatt K. Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs. Vet Med Sci. 2018;4(3):237-251.
Hay JK, Larson VS. Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors. Can Vet J. 2019;60(12):1326-1330.
Sauerbrey ML, Mullins MN, Bannink EO, et al. Lomustine and prednisone as first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). J Am Vet Med Assoc. 2007;230(12):1866-1869.
Matsuyama A, Poirier VJ, Mantovani F, Foster RA, Mutsaers AJ. Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic hemangiosarcoma. J Am Anim Hosp Assoc. 2017;53(6):304-312.
Allstadt SD, Rodriguez CO, Boostrom B, et al. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs. J Vet Intern Med. 2015;29(1):261-267.
Lucroy MD, Phillips BS, Kraegel SA, Simonson ER, Madewell BR. Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma. J Vet Intern Med. 1998;12(5):325-329.
Dank G, Rassnick KM, Sokolovsky Y, et al. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Vet Comp Oncol. 2012;12(1):78-84.
Saam DE, Liptak JM, Stalker MJ, Chun R. Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006). J Am Vet Med Assoc. 2011;238(2):195-206.
Murphy S, Hayes AM, Blackwood L, et al. Oral malignant melanoma-the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. Vet Comp Oncol. 2005;3(4):222-229.
Harding K, Bergman N, Smith A, et al. Response rate to a single dose of vinblastine administered to dogs with treatment-naïve multicentric lymphoma. Vet Comp Oncol. 2018;16(4):636-641.
Lenz JA, Robat CS, Stein TJ. Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014). J Small Anim Pract. 2016;57(8):429-434.
Rassnick KM, Bailey DB, Flory AB, et al. Efficacy of vinblastine for treatment of canine mast cell tumors. J Vet Intern Med. 2008;22(6):1390-1396.
Wouda RM, Miller ME, Chon E, Stein TJ. Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997-2012). J Am Vet Med Assoc. 2015;246(11):1230-1237.
Curran K, Thamm DH. Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol. Vet Comp Oncol. 2016;14(1):147-155.
Sorenmo K, Overley B, Krick E, et al. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. J Vet Intern Med. 2010;8(3):196-208.
Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med. 2002;16(6):704-709.
Vos N, Pellin M, Vail DM. A comparison of 12- and 19-week CHOP protocols using non-randomized, contemporaneous controls. Vet Comp Oncol. 2019;17(3):276-284.
Wolf-Ringwall A, Lopez L, Elmslie R, et al. Prospective evaluation of fow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol. Vet Comp Oncol. 2020;18(3):342-352.
Knapp DW, Henry CJ, Widmer WR, et al. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med. 2013;27(1):126-133.
Greene SN, Lucroy MD, Greenberg CB, Bonney PL, Knapp DW. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2007;231(7):1056-1060.
Marconato L, Chalfon C, Finotello R, et al. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: a multi-institutional retrospective study of the Italian Society of Veterinary Oncology. Vet Comp Oncol. 2019;17(4):537-544.
Burton JH, Garrett-Mayer E, Thamm DH. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. Vet Comp Oncol. 2013;11(4):306-315.
Giuffrida MA. A systematic review of adverse event reporting in companion animal clinical trials evaluating cancer treatment. J Am Vet Med Assoc. 2016;249(9):1079-1087.
Vail M. Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity. Top Companion Anim Med. 2009;24(3):122-129.
Britton BM, Kelleher ME, Gregor TP, Sorenmo KU. Evaluation of factors associated with prolonged hospital stay and outcome of febrile neutropenic patients receiving chemotherapy: 70 cases (1997-2010). Vet Comp Oncol. 2014;12(4):266-276.
Chretin JD, Rassnick KM, Shaw NA, et al. Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: a double-blind, placebo-controlled study. J Vet Intern Med. 2007;21(1):141-148.
Jugan MC, Wouda RM, Higginbotham ML. Preliminary evaluation of probiotic effects on gastrointestinal signs in dogs with multicentric lymphoma undergoing multi-agent chemotherapy: a randomised, placebo-controlled study. Vet Rec Open. 2021;8(1):e2.
Turek MM, Forrest LJ, Adams WM, Helfand SC, Vail DM. Postoperative radiotherapy and mitoxantrone for anal sac adenocarcinoma in the dog: 15 cases (1991-2001). Vet Comp Oncol. 2003;1(2):94-104.
Vickery KR, Wilson H, Vail MD, et al. Dose-escalating vinblastine for the treatment of canine mast cell tumor. Vet Comp Oncol. 2008;6(2):111-119.
Vaughan A, Johnson JL, Williams LE. Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol. J Vet Intern Med. 2007;21(6):1332-1339.
Childress O, Ramos-Vara JA, Ruple A. A randomized controlled trial of the effect of prednisone omission from a multidrug chemotherapy protocol on treatment outcome in dogs with peripheral nodal lymphomas. J Am Vet Med Assoc. 2016;249(9):1067-1078.
Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the bladder. J Vet Intern Med. 1994;8(4):273-278.
Schmidt BR, Glickman NW, DeNicola DB, et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc. 2001;218(11):1783-1786.
Marconato L, Zini E, Lindner D, et al. Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2011;238(8):1004-1010.